Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
REMOXIPRIDE VERSUS THIORIDAZINE IN THE TREATMENT OF FIRST EPISODES OFSCHIZOPHRENIA IN DRUG-NAIVE PATIENTS - A CASE FOR SPECIFIC, LOW POTENCY D-2 ANTAGONISTS
Autore:
LAMBERT T; KEKS N; MCGRATH J; CATTS S; HUSTIG H; VADDADI K; BURROWS G; VARGHESE F; GEORGE T; KERR K; JOHNSON G; BURNETT P; ZORBAS A; HILL C; COPOLOV D;
Indirizzi:
UNIV DEPT PSYCHIAT,MILLS ST CLIN RES UNIT,35 MILLS ST PERTH WA 6102 AUSTRALIA MONASH UNIV,ALFRED HOSP MELBOURNE VIC 3181 AUSTRALIA WOLSTON PK HOSP BRISBANE QLD AUSTRALIA PRINCE WALES HOSP SYDNEY NSW AUSTRALIA GLENSIDE HOSP ADELAIDE SA AUSTRALIA MAROONDAH HOSP MELBOURNE VIC AUSTRALIA AUSTIN HOSP MELBOURNE VIC 3084 AUSTRALIA PRINCESS ALEXANDRA HOSP WOOLLOONGABBA QLD 4102 AUSTRALIA PRINCE CHARLES HOSP BRISBANE QLD 4032 AUSTRALIA ROZELLE HOSP SYDNEY NSW AUSTRALIA REPATRIAT GEN HOSP SYDNEY NSW AUSTRALIA HILLCREST HOSP ADELAIDE SA AUSTRALIA SIR CHARLES GAIRDINER HOSP PERTH 6000 WA AUSTRALIA MENTAL HLTH RES INST MELBOURNE VIC AUSTRALIA
Titolo Testata:
Human psychopharmacology
fascicolo: 6, volume: 10, anno: 1995,
pagine: 455 - 460
SICI:
0885-6222(1995)10:6<455:RVTITT>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Keywords:
NEUROLEPTIC DRUGS; DRUG THERAPY; SIDE-EFFECTS (DRUG); SCHIZOPHRENIA; THIORIDAZINE; REMOXIPRIDE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Physical, Chemical & Earth Sciences
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
7
Recensione:
Indirizzi per estratti:
Citazione:
T. Lambert et al., "REMOXIPRIDE VERSUS THIORIDAZINE IN THE TREATMENT OF FIRST EPISODES OFSCHIZOPHRENIA IN DRUG-NAIVE PATIENTS - A CASE FOR SPECIFIC, LOW POTENCY D-2 ANTAGONISTS", Human psychopharmacology, 10(6), 1995, pp. 455-460

Abstract

Remoxipride, a substituted benzamide, is a selective D-2 antagonist with an atypical neuroleptic profile. Previous studies have demonstrated its antipsychotic efficacy against haloperidol and, more recently, thioridazine. Of the 144 patients enrolled in the Australian remoxipride-thioridazine comparative trial, 28 presented for their first episodeof schizophrenia and/or had no previous neuroleptic treatment. These patients form the subject of this paper. The study found that in persons presenting for their first admission for schizophrenia, remoxiprideshowed equal antipsychotic efficacy compared to thioridazine. Treatments were comparable in terms of generating few extrapyramidal symptomsbut thioridazine caused more significant general side-effects. Patients are more likely to be compliant with remoxipride due to its tolerability. Despite remoxipride being withdrawn from the market due to a suggested association with aplastic anaemia, this class of substituted benzamides warrants further examination as a treatment agent for first and subsequent episodic psychosis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 16:28:41